Compounds > trifluoromethylpyridine
Page last updated: 2024-12-08

trifluoromethylpyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trifluoromethylpyridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID136199
SCHEMBL ID84051
MeSH IDM0361404

Synonyms (35)

Synonym
AC-14614
2-(1,1,1-trifluoromethyl)pyridine
pyridine, 2-(trifluoromethyl)-
2-(cf3)-pyridine
2-(trifluoromethyl)pyridine, 97%
368-48-9
2-(trifluoromethyl)pyridine ,
AKOS005063719
FT-0650775
A6341
2-(trifluoromethyl)-pyridine
2-trifluoromethyl-pyridine
a,a,a-trifluoro-2-picoline
BP-10524
FT-0608977
alpha,alpha,alpha-trifluoro-2-picoline
AM20070015
2-trifluoromethylpyridine
(trifluoromethyl)pyridine
trifluoromethylpyridine
trifluoromethyl pyridine
2-trifluoromethyl pyridine
SCHEMBL84051
MB02365
SY006004
mfcd02183562
T2683
TS-01913
DS-0572
Q-101468
pyridine, (trifluoromethyl)-
DTXSID50190268
CS-D1741
EN300-104803
brqzooweldmgoe-uhfffaoysa-n

Research Excerpts

Overview

Trifluoromethylpyridine (TFMP) is a biologically active fragment formed by connecting trifluors and pyridine rings.

ExcerptReferenceRelevance
"Trifluoromethylpyridine (TFMP) is a biologically active fragment formed by connecting trifluoromethyl and pyridine ring. "( Trifluoromethylpyridine: An Important Active Fragment for the Discovery of New Pesticides.
Chi, YR; Dai, A; Jin, Z; Wu, J; Zheng, Z, 2022)		3.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's5 (41.67)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.		2.0210monochlorobenzenes;
N-arylpiperazine		drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic
quipazine
Quipazine: A pharmacologic congener of serotonin that contracts smooth muscle and has actions similar to those of tricyclic antidepressants. It has been proposed as an oxytocic.		2.0210piperazines;
pyridines
levodopa
Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease		2.0210amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
hydrazine
diamine : Any polyamine that contains two amino groups.		2.0510azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
fluorine
Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.		2.0510diatomic fluorine;
gas molecular entity		NMR chemical shift reference compound
thiourea
Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.		7.4110one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0210
Paralysis, Legs
[description not available]		02.0210
Injuries, Spinal Cord
[description not available]		02.0210
Paraplegia
Severe or complete loss of motor function in the lower extremities and lower portions of the trunk. This condition is most often associated with SPINAL CORD DISEASES, although BRAIN DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; and MUSCULAR DISEASES may also cause bilateral leg weakness.		02.0210
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.0210